Cenci, Tonia
 Distribuzione geografica
Continente #
NA - Nord America 4.704
EU - Europa 3.358
AS - Asia 3.108
SA - Sud America 510
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 91
OC - Oceania 7
Totale 11.899
Nazione #
US - Stati Uniti d'America 4.599
DE - Germania 1.346
SG - Singapore 1.247
CN - Cina 1.048
SE - Svezia 513
BR - Brasile 424
IT - Italia 352
VN - Vietnam 239
FR - Francia 236
UA - Ucraina 218
GB - Regno Unito 166
IE - Irlanda 132
IN - India 116
PL - Polonia 106
ID - Indonesia 84
FI - Finlandia 82
RU - Federazione Russa 61
TR - Turchia 60
JP - Giappone 55
BD - Bangladesh 52
HK - Hong Kong 51
MX - Messico 42
CA - Canada 35
IQ - Iraq 34
AR - Argentina 30
NL - Olanda 29
ZA - Sudafrica 28
ES - Italia 25
BE - Belgio 20
EC - Ecuador 16
IR - Iran 15
LT - Lituania 15
AT - Austria 14
MA - Marocco 13
CI - Costa d'Avorio 12
PK - Pakistan 12
KR - Corea 11
SA - Arabia Saudita 11
VE - Venezuela 10
TN - Tunisia 9
CL - Cile 8
JM - Giamaica 8
UZ - Uzbekistan 8
CH - Svizzera 7
CO - Colombia 7
NP - Nepal 7
PH - Filippine 7
AZ - Azerbaigian 6
DZ - Algeria 6
KE - Kenya 6
OM - Oman 5
PE - Perù 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
EG - Egitto 4
ET - Etiopia 4
EU - Europa 4
KW - Kuwait 4
LV - Lettonia 4
MD - Moldavia 4
RO - Romania 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
GE - Georgia 3
IL - Israele 3
JO - Giordania 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NI - Nicaragua 3
NO - Norvegia 3
PT - Portogallo 3
TW - Taiwan 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
AO - Angola 2
DO - Repubblica Dominicana 2
GR - Grecia 2
HR - Croazia 2
KG - Kirghizistan 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
RS - Serbia 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
VG - Isole Vergini Britanniche 2
XK - ???statistics.table.value.countryCode.XK??? 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
DK - Danimarca 1
GA - Gabon 1
GF - Guiana Francese 1
Totale 11.769
Città #
Ashburn 858
Singapore 701
Chandler 494
San Jose 356
Hangzhou 314
Beijing 186
Dublin 133
Jacksonville 133
Los Angeles 121
San Mateo 107
Nanjing 100
New York 99
Nürnberg 92
Ho Chi Minh City 87
Warsaw 87
Wilmington 84
Ann Arbor 83
Jakarta 75
Lauterbourg 74
Woodbridge 71
The Dalles 69
Houston 68
Dearborn 61
Fairfield 57
Seattle 57
Hanoi 50
Cattolica 49
Munich 49
Izmir 47
Frankfurt am Main 46
Hong Kong 46
Milan 45
Rome 45
Chicago 44
Tokyo 44
Nanchang 42
Boston 41
Helsinki 36
Moscow 36
Hefei 35
Lawrence 35
Princeton 33
São Paulo 33
Bremen 29
Hyderabad 29
Redwood City 29
Council Bluffs 26
Kunming 26
Santa Clara 26
Redmond 25
Marseille 24
Orem 24
Shanghai 23
Stockholm 22
Dallas 20
Paris 20
Atlanta 19
Lancaster 19
Shenyang 19
Buffalo 18
Mountain View 18
Brussels 17
Denver 17
Johannesburg 16
Cambridge 15
Guangzhou 15
Hebei 15
London 15
Baghdad 14
Boardman 14
Brooklyn 14
Norwalk 14
Tianjin 14
Jiaxing 13
Phoenix 13
Abidjan 12
Changsha 12
Haiphong 11
Kraków 11
Leawood 11
Memphis 11
Nuremberg 11
Poplar 11
Porto Alegre 11
Seoul 11
Dhaka 10
Kent 10
Manchester 10
Rio de Janeiro 10
San Francisco 10
Toronto 10
Zhengzhou 10
Amsterdam 9
Augusta 9
Chennai 9
Düsseldorf 9
Fremont 9
Mexico City 9
Montreal 9
Mumbai 9
Totale 6.199
Nome #
Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection 618
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells 512
Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas 400
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 327
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System 270
Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study 259
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 255
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 236
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 213
Von hippel-lindau disease and erythrocytosis 209
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 191
Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience 186
PDGFRA-mutant syndrome 186
Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. 184
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 176
The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma 175
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis 171
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. 170
Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. 167
Diagnostic and prognostic value of immunocytochemistry and braf mutation analysis on liquid based biopsies of thyroid neoplasms suspicious for carcinoma. 163
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 162
Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease 149
The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia 148
Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin 148
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior 147
A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis 146
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. 143
Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior 142
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 142
Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma 141
Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases 141
Methylation study of the Paris system for reporting urinary (TPS) categories 141
PTTG1/ZEB1 Axis Regulates E-Cadherin Expression in Human Seminoma 140
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms 140
Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression 138
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 137
Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis 134
DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group 133
Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights 132
The mutant JAK2 allele burden in children with essential thrombocythemia 131
The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms 131
SPTBN1 Mediates the Cytoplasmic Constraint of PTTG1, Impairing Its Oncogenic Activity in Human Seminoma 128
Divergent gastrointestinal stromal tumors in syndromic settings 126
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis 125
Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. 125
Chemotherapy of Skull Base Chordoma Tailored on Responsiveness of Patient-Derived Tumor Cells to Rapamycin1,2 124
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma 122
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 120
Telomerase inhibition in malignant gliomas. A systematic review 119
Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach 118
Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis 117
Epigenetic Silencing of Id4 Identifies a Glioblastoma Subgroup With a Better Prognosis as a Consequence of an Inhibition of Angiogenesis 116
Plexiform architecture in gastrointestinal stromal tumors is not restricted to succinate dehydrogenase-deficient cases 115
how limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid based cytology. Role of TERT promoter and BRAF V600E mutation analysis 114
Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms 112
Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules 108
Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules 107
Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme 105
Pituitary-tumour-transforming-gene 1 expression in testicular cancer 105
Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma 104
The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? 103
Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas 102
Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. 101
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 101
Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report 99
Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis 98
Erratum: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells (Nature (2010) 468 (824-828)) 98
The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature 96
To obtain more with less cytologic samples with ancillary molecular techniques-the useful role of liquid-based cytology 94
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 90
The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies with Aggressive Behavior 85
Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin 76
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 73
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response 71
The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior 61
Totale 11.899
Categoria #
all - tutte 45.333
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.333


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022591 0 42 16 64 57 20 16 96 28 45 87 120
2022/20231.344 196 198 101 208 93 159 54 85 155 28 47 20
2023/20241.116 27 203 25 50 16 92 265 261 6 30 65 76
2024/20251.277 32 29 119 40 106 51 44 55 179 145 255 222
2025/20263.559 490 121 193 432 660 191 659 171 236 231 111 64
2026/2027467 121 346 0 0 0 0 0 0 0 0 0 0
Totale 11.899